3.95
+0.02(+0.51%)
Currency In USD
Address
1901 West 47th Place
Kansas City, KS 66205
United States of America
Phone
913 942 2300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
December 08, 2021
| Name | Title | Pay | Year Born |
| Dr. Shane J. Schaffer Pharm.D. | Co-Founder, Chief Executive Officer & Chairman of the Board | 570,781 | 1975 |
| Dr. Matthew N. Brams M.D. | Co-Founder, Executive Vice President & Chief Medical Officer | 244,792 | 1964 |
| Dr. Laurie A. Myers M.B.A., Ph.D. | Executive Vice President & Chief Operating Officer | 367,467 | 1957 |
| Thomas Dalton | Vice President of Investor & Public Relations | 0 | N/A |
| Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President & Chief Science Officer | 0 | 1958 |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.